An experimental drug was effective against malaria in a new study, potentially offering a much-needed buffer against the rising threat of drug resistance.
The drug, known as GanLum, is made by Swiss pharmaceutical giant Novartis. In a late-stage trial, it worked about as well as existing treatments against malaria – but it was also highly effective against mutant strains that show signs of resistance to the current drugs.
Once pathogens like parasites or bacteria evolve to the point where
Continue Reading on Euronews
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.